BioWorld

Sep. 9, 2005

View Archived Issues

Replidyne Raises $62.5M; Health Care Remains Top Dog For VCs

As its first product nears the market for respiratory infections, Replidyne Inc. brought in $62.5 million in a Series D round. (BioWorld Today) Read More

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Read More

Amicus Series C Garners $55M For Enzyme Efforts

Read More

Caliper Adding Size Through $22M NovaScreen Purchase

Read More

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Read More

Life Science Firms Giving To Help Katrina's Victims

Read More

Other News To Note

Read More